English | 简体中文 | 繁體中文 | 한국어
Share:
Invitation to a Q&A teleconference with Outotec

OUTOTEC OYJ  PRESS RELEASE MARCH 20, 2017  3:00 PM

Invitation to a Q&A teleconference with Outotec

The Q&A teleconference with CEO Markku Teräsvasara will be held on Monday, March 27, 2017 at 2:00 PM (Finnish time).

JOINING THE TELECONFERENCE AND PRESENTING QUESTIONS

Dial in 5-10 minutes prior to the start time using the number/confirmation code below.

Conference ID: 8790382

United Kingdom: +44 (0)330 336 9105
Finland: +358 (0)9 7479 0361
Sweden: +46 (0)8 5033 6574
United States of America: +1 719 325 2385

In addition, questions may be sent in advance via email to riitta.lind(at)outotec.com by March 27 at 10:00 AM. The recording of the teleconference and transcript will be published and stored on Outotec's website for on demand listening.

The contact information is gathered for registration purposes only and it is not used for commercial purposes.

The aim of the CEO's Q&A teleconferences is to give further clarity on information, which has been made public already earlier. Therefore, the company does not intend to publish separate announcements in connection with these sessions. In order to serve the capital market efficiently, and ensure equal access to company-related information, the teleconference is recorded and it is available on demand for future references.

OUTOTEC OYJ

Rita Uotila, Vice President - Investor Relations
tel. +358 20 529 2003
e-mail: rita.uotila(at)outotec.com

DISTRIBUTION:
Main media
www.outotec.com





This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Outotec Oyj via Globenewswire

Copyright © Thomson Reuters 2018. All rights reserved.
Press Releases
Orion to sell its Orion Diagnostica division - Due to the transaction Orion updates its outlook  
Apr 21, 2018 00:30 ET
Helsinn Group announces the FDA approval of the IV formulation of AKYNZEO® (fosnetupitant/ palonosetron) in the United States  
Apr 20, 2018 21:33 ET
BOURBON: Positive progress in negotiations with lenders  
Apr 20, 2018 18:30 ET
Hubbell Incorporated Declares Regular Quarterly Dividend  
Apr 20, 2018 16:01 ET
Helsinn Group announces the FDA approval of the IV formulation of AKYNZEO® (fosnetupitant/ palonosetron) in the United States  
Apr 20, 2018 15:23 ET
Heineken Holding N.V. - Amendments to the Articles of Association  
Apr 20, 2018 15:18 ET
Lubrizol Presents Estane® TPU and Other Innovations for Consumer, Industrial, Footwear and Electronics Applications at Chinaplas 2018  
Apr 20, 2018 12:03 ET
Lipotec Active Ingredients Becomes Umbrella Brand  
Apr 19, 2018 23:43 ET
LEH PHARMA LTD.: Company Update  
Apr 18, 2018 19:34 ET
Tusk Therapeutics presents data on to its anti-CD25 programme at AACR Annual Meeting 2018  
Apr 18, 2018 19:33 ET
More News >>
Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 5791 1818

Connect With us: